Imricor Medical Systems Past Earnings Performance
Past criteria checks 0/6
Imricor Medical Systems's earnings have been declining at an average annual rate of -12.9%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 2.1% per year.
Key information
-12.9%
Earnings growth rate
9.6%
EPS growth rate
Medical Equipment Industry Growth | 5.8% |
Revenue growth rate | 2.1% |
Return on equity | n/a |
Net Margin | -2,458.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now
May 08Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?
Jun 17Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely
Jul 08Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?
Mar 23We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely
May 09When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?
Feb 28We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully
Jan 24What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?
Dec 02What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition
Aug 18Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)
Jun 25Revenue & Expenses Breakdown
How Imricor Medical Systems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1 | -20 | 7 | 8 |
31 Mar 24 | 1 | -21 | 7 | 8 |
31 Dec 23 | 1 | -23 | 8 | 8 |
30 Sep 23 | 1 | -20 | 8 | 8 |
30 Jun 23 | 0 | -17 | 8 | 7 |
31 Mar 23 | 1 | -17 | 8 | 8 |
31 Dec 22 | 1 | -17 | 8 | 8 |
30 Sep 22 | 1 | -18 | 8 | 9 |
30 Jun 22 | 1 | -20 | 9 | 9 |
31 Mar 22 | 1 | -20 | 9 | 10 |
31 Dec 21 | 1 | -20 | 9 | 10 |
30 Sep 21 | 1 | -18 | 8 | 9 |
30 Jun 21 | 1 | -17 | 7 | 8 |
31 Mar 21 | 1 | -15 | 7 | 7 |
31 Dec 20 | 1 | -12 | 6 | 6 |
30 Sep 20 | 1 | -13 | 5 | 5 |
30 Jun 20 | 1 | -14 | 5 | 4 |
31 Mar 20 | 1 | -14 | 4 | 4 |
31 Dec 19 | 1 | -13 | 3 | 4 |
30 Sep 19 | 1 | -11 | 3 | 4 |
30 Jun 19 | 0 | -8 | 2 | 4 |
31 Mar 19 | 1 | -7 | 2 | 4 |
31 Dec 18 | 1 | -5 | 2 | 4 |
31 Dec 17 | 0 | -5 | 2 | 4 |
31 Dec 16 | 1 | -4 | 2 | 3 |
Quality Earnings: IMR is currently unprofitable.
Growing Profit Margin: IMR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMR is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare IMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).
Return on Equity
High ROE: IMR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 23:46 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Imricor Medical Systems, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Elyse Shapiro | Bell Potter |
Sarah Mann | MA Moelis Australia Securities Pty Ltd |
Scott Power | Morgans Financial Limited |